Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins-Reference-Cited by-同舟云学术

Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

Published:2021-05 Issue:5 Volume:27 Page:671-686
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Wagenlehner Florian,Lucenteforte Ersilia,Pea Federico,Soriano Alex,Tavoschi Lara,Steele Victoria R.,Henriksen Anne Santerre,Longshaw Christopher,Manissero Davide,Pecini Raymond,Pogue Jason M.

Funder

Shionogi

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference264 articles.

1. Toxicity in patients;Pogue;Adv Exp Med Biol,2019

2. ECDC antimicrobial consumption annual epidemiological report,2017

3. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies;Oliota;Diagn Microbiol Infect Dis,2019

4. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis;Chien;Int J Antimicrob Agents,2020

5. New information about the polymyxin/colistin class of antibiotics;Molina;Expert Opin Pharmacother,2009

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin;International Journal of Antimicrobial Agents;2024-02

2. Comparative pharmacokinetics of polymyxin B in critically ill elderly patients with extensively drug-resistant gram-negative bacteria infections;Frontiers in Pharmacology;2024-02-01

3. Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed metallo-β-lactamase production: a systematic review and meta-analysis;Expert Review of Anti-infective Therapy;2024-01-23

4. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections;Journal of Infection and Chemotherapy;2024-01

5. A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol;Infectious Diseases and Therapy;2023-12-16